Despite Pressure, Biogen’s Alzheimer’s Drug Still a Likely Blockbuster

Despite Pressure, Biogen’s Alzheimer’s Drug Still a Likely Blockbuster
Worries over the drug’s price and whether Medicare will cover it have sparked a selloff in Biogen—and given investors a fresh opportunity.
WSJ.com: Markets